http://cancergrace.org/lung Expert-mediated discussion of cancer management Thu, 24 May 2012 11:23:01 +0000 en hourly 1 http://wordpress.org/?v=3.3.1 Expert-mediated discussion of cancer management GRACE :: Lung Cancer no Expert-mediated discussion of cancer management http://cancergrace.org/lung/wp-content/plugins/powerpress/rss_default.jpg http://cancergrace.org/lung http://cancergrace.org/lung/2012/05/21/top5-sclc-early-nsclc/ http://cancergrace.org/lung/2012/05/21/top5-sclc-early-nsclc/#comments Tue, 22 May 2012 04:36:45 +0000 Dr West http://cancergrace.org/lung/?p=10626 http://cancergrace.org/lung/2012/05/21/top5-sclc-early-nsclc/feed/ 0 http://cancergrace.org/lung/2012/05/19/my-top-5-notable-asco-2012-abstracts-in-metastatic-nsclc/ http://cancergrace.org/lung/2012/05/19/my-top-5-notable-asco-2012-abstracts-in-metastatic-nsclc/#comments Sun, 20 May 2012 01:26:41 +0000 Dr West http://cancergrace.org/lung/?p=10537 http://cancergrace.org/lung/2012/05/19/my-top-5-notable-asco-2012-abstracts-in-metastatic-nsclc/feed/ 4 http://cancergrace.org/lung/2012/05/15/modifying-factors-adjuvant-chemo/ http://cancergrace.org/lung/2012/05/15/modifying-factors-adjuvant-chemo/#comments Wed, 16 May 2012 03:37:53 +0000 Dr West http://cancergrace.org/lung/?p=10354 http://cancergrace.org/lung/2012/05/15/modifying-factors-adjuvant-chemo/feed/ 2 http://cancergrace.org/lung/2012/05/12/spigel-on-markers-in-clin-trials/ http://cancergrace.org/lung/2012/05/12/spigel-on-markers-in-clin-trials/#comments Sun, 13 May 2012 00:07:07 +0000 Dr West http://cancergrace.org/lung/?p=10191 http://cancergrace.org/lung/2012/05/12/spigel-on-markers-in-clin-trials/feed/ 0 ALK Rearrangement,clinical trial design,EGFR mutation,FGFR,KRAS mutation,molecular marker,Molecular Oncology,NSCLC,NSCLC histology,patient characteristics Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity.  In this podcast, my friend Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity.  In this podcast, my friend Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN presents on the benefits as well as the challenges of new models of clinical trials in lung cancer that move away from "all comers" to smaller, more limited populations defined by molecular markers.   Following his presentation, we continued our panel discussion, covering how much the transition into molecular oncology has disrupted how we do clinical research, as well as how our growing experience with molecular testing is leading us to question some of our previously held beliefs.   Below are the audio and video versions of this podcast, along with the transcript and figures for it. Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Audio Podcast Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Transcript Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Figs The last part of the program will be Dr. Glen Goss speaking on efforts to integrate collection of molecular markers across a network or health care system -- look for that soon. And thanks again to LUNGevity Foundation for partnering with us to produce this program and the subsequent podcasts produced from it. Finally, I'll just say that I do intend to write some of my own new posts soon.  For now, I'm still working to catch up on several other commitments that were put on ice so that I could get through my recent grueling medical board recertification.  I'll be digging myself out soon. GRACE :: Lung Cancer no 24:30 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=10191-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/05/08/its-asco-season-join-us-to-discuss-lung-cancer-highlights-on-june-28th/ http://cancergrace.org/lung/2012/05/08/its-asco-season-join-us-to-discuss-lung-cancer-highlights-on-june-28th/#comments Wed, 09 May 2012 03:36:32 +0000 Dr West http://cancergrace.org/lung/?p=9970 http://cancergrace.org/lung/2012/05/08/its-asco-season-join-us-to-discuss-lung-cancer-highlights-on-june-28th/feed/ 1 http://cancergrace.org/lung/2012/05/03/webinar-on-pulmonary-complications-in-lung-cancer-with-pulmonologist-gerard-silvestri/ http://cancergrace.org/lung/2012/05/03/webinar-on-pulmonary-complications-in-lung-cancer-with-pulmonologist-gerard-silvestri/#comments Fri, 04 May 2012 04:44:47 +0000 Dr West http://cancergrace.org/lung/?p=9762 http://cancergrace.org/lung/2012/05/03/webinar-on-pulmonary-complications-in-lung-cancer-with-pulmonologist-gerard-silvestri/feed/ 1 http://cancergrace.org/lung/2012/05/01/sm-part-4-panel-disc/ http://cancergrace.org/lung/2012/05/01/sm-part-4-panel-disc/#comments Tue, 01 May 2012 14:47:41 +0000 Dr West http://cancergrace.org/lung/?p=9664 http://cancergrace.org/lung/2012/05/01/sm-part-4-panel-disc/feed/ 2 ALK Rearrangement,EGFR mutation,FGFR,KRAS mutation,molecular marker,Molecular Oncology,NSCLC,NSCLC histology,patient characteristics,smoking status Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss.  We continued our animated discussion on the promise as well as the pitfalls of ... Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss.  We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.  Below you'll find the audio and video versions of the podcast, along with the transcript (no real figures to go with this one). Molecular Markers SM Pt 4 Panel Discussion Audio Podcast Molecular Markers SM Pt 4 Panel Discussion Transcript We'll continue with a presentation by Dr. Spigel on the value and challenges of incorporating molecular markers into the design of clinical trials in lung cancer. GRACE :: Lung Cancer no 16:57 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=9664-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/04/26/zhu-jama-avastin/ http://cancergrace.org/lung/2012/04/26/zhu-jama-avastin/#comments Thu, 26 Apr 2012 16:57:36 +0000 Dr West http://cancergrace.org/lung/?p=9468 http://cancergrace.org/lung/2012/04/26/zhu-jama-avastin/feed/ 3 http://cancergrace.org/lung/2012/04/24/molecular-markers-webinar-part-3-panel-discussion-debating-who-to-test-and-what-to-test-for/ http://cancergrace.org/lung/2012/04/24/molecular-markers-webinar-part-3-panel-discussion-debating-who-to-test-and-what-to-test-for/#comments Wed, 25 Apr 2012 01:54:55 +0000 Dr West http://cancergrace.org/lung/?p=9391 http://cancergrace.org/lung/2012/04/24/molecular-markers-webinar-part-3-panel-discussion-debating-who-to-test-and-what-to-test-for/feed/ 0 ALK Rearrangement,EGFR mutation,FGFR,KRAS mutation,molecular marker,Molecular Oncology,NSCLC,NSCLC histology,patient characteristics,smoking status Here is the next portion of our special webinar on molecular markers in advanced NSCLC, featuring Drs. Charlie Rudin from Johns Hopkins,  Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Here is the next portion of our special webinar on molecular markers in advanced NSCLC, featuring Drs. Charlie Rudin from Johns Hopkins,  Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Glen Goss from the University of Ottawa and NCI-Canada's Lung Cancer Committee.    In this continuing portion of the program, we have a debate on the merits of uniform vs. more selective testing of "druggable" mutations and consider whether it is more attractive to test for multiple markers simultaneous or perhaps sequentially, since they are typically mutually exclusive.  We also discuss the challenge of the delays in treatment that may become a real clinical problem for some patients if testing may require a few weeks of downtime. Below you'll find the audio and video versions of the podcast, along with the transcript and figures for this activity. Molecular Markers SM Pt 3 Panel Discussion Audio Podcast Molecular Markers SM Pt 3 Panel Discussion Transcript Molecular Markers SM Pt 3 Panel Discussion Figs We'll continue this rather intense discussion in the next podcast, coming soon.     GRACE :: Lung Cancer no 17:28 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=9391-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/04/22/false-neg-biopsies-of-lung-nodules/ http://cancergrace.org/lung/2012/04/22/false-neg-biopsies-of-lung-nodules/#comments Sun, 22 Apr 2012 23:11:56 +0000 Dr West http://cancergrace.org/lung/?p=9274 http://cancergrace.org/lung/2012/04/22/false-neg-biopsies-of-lung-nodules/feed/ 6 http://cancergrace.org/lung/2012/04/15/dr-alice-shaw-on-clinical-factors-associated-with-molecular-markers/ http://cancergrace.org/lung/2012/04/15/dr-alice-shaw-on-clinical-factors-associated-with-molecular-markers/#comments Sun, 15 Apr 2012 22:03:45 +0000 Dr West http://cancergrace.org/lung/?p=9019 http://cancergrace.org/lung/2012/04/15/dr-alice-shaw-on-clinical-factors-associated-with-molecular-markers/feed/ 0 Alice Shaw,ALK Rearrangement,CancerGRACE,EGFR mutation,FGFR,GRACE,GRACEcast,KRAS mutation,Massachusetts General Hospital,MGH,molecular marker,Molecular Oncology I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs. I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs. Charles Rudin (Johns Hopkins University in Balimore, MD), Alice Shaw (Massachusetts General Hospital in Boston, MA), David Spigel (Sarah Cannon Cancer Center in Nashville, TN), and Glen Gloss (University of Ottawa in Ontario, Canada).   In this short podcast, Dr. Alice Shaw reviewed the frequencies of different molecular markers in advanced NSCLC as a function of patient sex, smoking status, race, and tumor histology.  This work is very interesting, of course, because if we only do molecular marker studies of people with an adenocarcinoma or never-smokers, we not only won't ever find potentially relevant mutations in people with other histologies and those with a smoking history, but we won't have any good idea of the probabilities of finding them either. Here is the podcast in audio and video formats, as well as the transcript and figures. Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Audio Podcast Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Transcript Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Figs I certainly found her presentation interesting, particularly since it highlighted some potentially fruitful targets in squamous cell carcinoma, such an underserved cancer population overdue for new treatments.   GRACE :: Lung Cancer no 10:48 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=9019-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/04/10/molecular-markers-in-lung-cancer-dr-charlie-rudin-on-the-lung-cancer-mutation-consortium/ http://cancergrace.org/lung/2012/04/10/molecular-markers-in-lung-cancer-dr-charlie-rudin-on-the-lung-cancer-mutation-consortium/#comments Tue, 10 Apr 2012 14:47:52 +0000 Dr West http://cancergrace.org/lung/?p=8851 http://cancergrace.org/lung/2012/04/10/molecular-markers-in-lung-cancer-dr-charlie-rudin-on-the-lung-cancer-mutation-consortium/feed/ 1 Advanced NSCLC,ALK Rearrangement,Charles Rudin,CLIA lab,EGFR mutation,Johns Hopkins,KRAS mutation,LCMC,lung adenocarcinoma,Lung Cancer Mutation Consortium,molecular marker,Molecular Oncology This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica "Targeted Therapies in Lung Cancer" meeting several weeks ago.  There, This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica "Targeted Therapies in Lung Cancer" meeting several weeks ago.  There, I was privileged to be joined by four excellent guest faculty members -- Dr. Charles Rudin from Johns Hopkins University in Baltimore, Dr. Alice Shaw from Massachusetts General Hospital in Boston, Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, and Dr. Glen Goss from the University of Ottawa.  They each brought their rich experience and some differing perspectives on the complex and evolving topic of how to apply new work on molecular markers in lung cancer to clinical practice. Below you'll find links to the audio and video versions of the podcast, along with the transcript and figures.   Molecular Markers SM Pt 1 Rudin on LCMC Audio Podcast Molecular Markers SM Pt 1 Rudin on LCMC Transcript Molecular Markers SM Pt 1 Rudin on LCMC Figures This program also includes additional discussion before and after his presentation, as the webinar featured both presentations by the guest faculty and a panel discussion about the most timely questions in the field.  It was a lot of fun for me and our panel, and I hope you find it both interesting and educational. The next part will be Dr. Shaw speaking on their experience of broadly molecularly profiling their patients at Massachusetts General Hospital for markers and what they've learned from that work. GRACE :: Lung Cancer no 17:36 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=8851-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/04/09/low-testosterone-with-xalkori-crizotinib-a-newly-identified-side-effect/ http://cancergrace.org/lung/2012/04/09/low-testosterone-with-xalkori-crizotinib-a-newly-identified-side-effect/#comments Mon, 09 Apr 2012 16:55:56 +0000 Dr West http://cancergrace.org/lung/?p=8819 http://cancergrace.org/lung/2012/04/09/low-testosterone-with-xalkori-crizotinib-a-newly-identified-side-effect/feed/ 2 http://cancergrace.org/lung/2012/04/03/radiation-to-address-cells-with-resistance-to-targeted-therapies/ http://cancergrace.org/lung/2012/04/03/radiation-to-address-cells-with-resistance-to-targeted-therapies/#comments Tue, 03 Apr 2012 23:27:35 +0000 Dr. Weiss http://cancergrace.org/lung/?p=8592 http://cancergrace.org/lung/2012/04/03/radiation-to-address-cells-with-resistance-to-targeted-therapies/feed/ 29 http://cancergrace.org/lung/2012/03/30/qa-lc-highlights-weiss/ http://cancergrace.org/lung/2012/03/30/qa-lc-highlights-weiss/#comments Fri, 30 Mar 2012 23:23:06 +0000 Dr West http://cancergrace.org/lung/?p=8431 http://cancergrace.org/lung/2012/03/30/qa-lc-highlights-weiss/feed/ 7 acquired resistance,afatinib,c-MET,CancerGRACE,cetuximab,EGFR mutation,GRACE,GRACEcast,Heat shock protein,HSP90,Jared Weiss,Lung Cancer Here's the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 -- the question and answer session that followed his presentation.  Below is the transcript, figures, Here's the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 -- the question and answer session that followed his presentation.  Below is the transcript, figures, and the audio and video versions of the podcast. Dr. Weiss Lung Cancer Highlights 2011 Q and A Transcript Dr. Weiss Lung Cancer Highlights 2011 Q and A Session Figs Dr. Weiss Lung Cancer Highlights 2011 Q and A Session Audio Podcast   I hope you find our program with Dr. Weiss interesting and helpful. Next we'll be pushing out the discussion and presentations from the Santa Monica conference    GRACE :: Lung Cancer no 18:14 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=8431-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/03/27/refining-ct-based-lung-cancer-screening-with-a-blood-test/ http://cancergrace.org/lung/2012/03/27/refining-ct-based-lung-cancer-screening-with-a-blood-test/#comments Tue, 27 Mar 2012 17:57:16 +0000 Dr West http://cancergrace.org/lung/?p=8251 http://cancergrace.org/lung/2012/03/27/refining-ct-based-lung-cancer-screening-with-a-blood-test/feed/ 3 http://cancergrace.org/lung/2012/03/24/gtx-024-sarm-acs-cachexia/ http://cancergrace.org/lung/2012/03/24/gtx-024-sarm-acs-cachexia/#comments Sat, 24 Mar 2012 17:39:12 +0000 Dr West http://cancergrace.org/lung/?p=8083 http://cancergrace.org/lung/2012/03/24/gtx-024-sarm-acs-cachexia/feed/ 2 http://cancergrace.org/lung/2012/03/22/dr-weisss-highlights-in-lung-cancer-2011-ct-screening-optimal-management-of-elderly-patients-with-advanced-nsclc/ http://cancergrace.org/lung/2012/03/22/dr-weisss-highlights-in-lung-cancer-2011-ct-screening-optimal-management-of-elderly-patients-with-advanced-nsclc/#comments Thu, 22 Mar 2012 18:49:47 +0000 Dr West http://cancergrace.org/lung/?p=7998 http://cancergrace.org/lung/2012/03/22/dr-weisss-highlights-in-lung-cancer-2011-ct-screening-optimal-management-of-elderly-patients-with-advanced-nsclc/feed/ 0 CancerGRACE,Chest CT,CT screening,GRACE,GRACEcast,Jared Weiss,Lung Cancer,Lung Cancer in Elderly,lung cancer screening,National Lung Screening Trial,NLST,NSCLC This is the third and final part of Dr. Weiss's presentation on "Highlights in Lung Cancer, 2011".  After focusing on developments in relatively narrow subpopulations with distinct molecular markers in the first two parts of his webinar, Dr. This is the third and final part of Dr. Weiss's presentation on "Highlights in Lung Cancer, 2011".  After focusing on developments in relatively narrow subpopulations with distinct molecular markers in the first two parts of his webinar, Dr. Weiss closed with his coverage of a couple of issues with broader applicability: the new data supporting CT screening for higher risk people with a significant smoking history, and also some new data addressing the question of whether elderly patients are best served by receiving single agent or doublet chemotherapy. Below you'll find the podcast of the program in audio and video formats, as well as the transcript and figures for this activity. Dr. Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Audio Podcast Dr. Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Transcript Dr Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Figs The last component of this program will be the Q&A session, which we'll be releasing in just a few days.   GRACE :: Lung Cancer no 13:57 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=7998-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/03/18/lung-cancer-highlights-2011-by-dr-weiss-part-2-alk-and-other-new-molecular-targets/ http://cancergrace.org/lung/2012/03/18/lung-cancer-highlights-2011-by-dr-weiss-part-2-alk-and-other-new-molecular-targets/#comments Sun, 18 Mar 2012 19:28:52 +0000 Dr West http://cancergrace.org/lung/?p=7832 http://cancergrace.org/lung/2012/03/18/lung-cancer-highlights-2011-by-dr-weiss-part-2-alk-and-other-new-molecular-targets/feed/ 1 ALK Rearrangement,crizotinib,EML4-ALK,Lung Cancer,NSCLC,ROS-1,ROS-1 mutation,targeted therapy,XALKORI Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss.  This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss.  This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, along with an impressive treatment for this subgroup, and other new targets, such as ROS-1.   Below you'll find the audio and video versions of the podcast, as well as the transcript and figures. Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Audio Podcast Dr. Weiss Lung Cancer  Highlights 2011, Pt 2 ALK and New Molecular Targets Transcript Dr. Weiss Lung Cancer Highlights 2011 Pt 2 ALK and New Molecular Targets Figs The third and final part of Dr. Weiss's presentation will focus on advances for broader populations: smokers and the elderly.  He'll cover the lung cancer screening trial known as the NLST, as well as an influential presentation of single agent vs. doublet chemotherapy in elderly patients with advanced NSCLC.  Look for that here very soon. Thanks again to LUNGevity Foundation for their sponsorship of this work with us, making this content possible. GRACE :: Lung Cancer no 8:21 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=7832-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/03/15/2011-highlights-in-lung-cancer-by-dr-jared-weiss-part-1-the-egfr-axis/ http://cancergrace.org/lung/2012/03/15/2011-highlights-in-lung-cancer-by-dr-jared-weiss-part-1-the-egfr-axis/#comments Thu, 15 Mar 2012 23:26:14 +0000 Dr West http://cancergrace.org/lung/?p=7710 http://cancergrace.org/lung/2012/03/15/2011-highlights-in-lung-cancer-by-dr-jared-weiss-part-1-the-egfr-axis/feed/ 8 acquired resistance,afatinib,c-MET,cetuximab,EGFR,EGFR mutation,erbitux,erlotinib,EURTAC,gefitinib,Iressa,Met-MAb Apologies for the long wait since our own Dr. Weiss's upbeat and thoughtful review of the leading stories about lung cancer in 2011.  Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, Apologies for the long wait since our own Dr. Weiss's upbeat and thoughtful review of the leading stories about lung cancer in 2011.  Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, so we've broken that up into several short pieces that cover a few highlights at a time.  In fact, we're going to make an effort to have podcasts shorter and easier to digest in the future.   The first part is on EGFR-based therapies, including the EURTAC trial of the EGFR tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) vs. standard doublet chemo in a European, EGFR mutation-positive patient population, followed by work on EGFR TKI/monoclonal antibody combinations: one being the single arm afatinib/Erbitux (cetuximab) for patients with acquired resistance after a good response to earlier EGFR TKI therapy, and the second being Tarceva with either the c-MET antibody MET-MAb or placebo.   Here's the audio and video versions of the podcast, along with the transcript and figures for this portion of the program.  Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Audio Podcast Dr. Weiss Lung Cancer Highlights  2011 Pt 1 EGFR Axis Transcript Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Figs We'll be putting out more pieces of this every few day or two, so look for the next part very soon.  Thanks to Dr. Weiss, and also to LUNGevity Foundation for partnering with us to make this program possible. GRACE :: Lung Cancer no 11:13 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=7710-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/03/14/tips-and-tools-on-smoking-cessation/ http://cancergrace.org/lung/2012/03/14/tips-and-tools-on-smoking-cessation/#comments Thu, 15 Mar 2012 03:56:52 +0000 Dr West http://cancergrace.org/lung/?p=7677 http://cancergrace.org/lung/2012/03/14/tips-and-tools-on-smoking-cessation/feed/ 0 5 As,bupropion,chantix,e-cigarette,lung cancer screening,nicotine,nicotine gum,nicotine patch,nicotine replacement,quit smoking,smoking cessation,varenicline This long-overdue podcast by Dr. Mark Millard, Medical Director of the Baylor Martha Foster Lung Care Center and Professor of Pulmonology at Baylor University in Dallas, TX, focuses on many aspects of smoking cessation: how physicians can effectively d... This long-overdue podcast by Dr. Mark Millard, Medical Director of the Baylor Martha Foster Lung Care Center and Professor of Pulmonology at Baylor University in Dallas, TX, focuses on many aspects of smoking cessation: how physicians can effectively discuss it with patients, how anyone can discuss the issue constructively with a smoker, and how someone motivated to quit can use a wide range of tools -- both behavioral and medical -- to optimize their chance of quitting for good. Here are the audio and video versions of the podcast, along with the transcript and figures for the program.   Dr. Millard Tips and Tools for Smoking Cessation Audio Podcast Dr. Millard Tips and Tools for Smoking Cessation Transcript Dr. Millard Tips and Tools for Smoking Cessation Figures   This program was produced in partnership with the LUNGevity Foundation, and we thank them for their support. Next up: The long-awaited "Highlights of Lung Cancer, 2011" podcasts from the presentation by Dr. Weiss several weeks ago.      GRACE :: Lung Cancer no 27:50 <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=7677-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2012/03/09/have-mutation-will-travel/ http://cancergrace.org/lung/2012/03/09/have-mutation-will-travel/#comments Fri, 09 Mar 2012 21:53:29 +0000 Dr West http://cancergrace.org/lung/?p=7469 http://cancergrace.org/lung/2012/03/09/have-mutation-will-travel/feed/ 9 http://cancergrace.org/lung/2012/03/01/new-forum-list-options/ http://cancergrace.org/lung/2012/03/01/new-forum-list-options/#comments Fri, 02 Mar 2012 04:11:07 +0000 Dr West http://cancergrace.org/lung/?p=7090 http://cancergrace.org/lung/2012/03/01/new-forum-list-options/feed/ 12 http://cancergrace.org/lung/2012/02/29/new-medscape-program-if-you-want-to-check-it-out/ http://cancergrace.org/lung/2012/02/29/new-medscape-program-if-you-want-to-check-it-out/#comments Thu, 01 Mar 2012 05:28:49 +0000 Dr West http://cancergrace.org/lung/?p=6973 http://cancergrace.org/lung/2012/02/29/new-medscape-program-if-you-want-to-check-it-out/feed/ 1 http://cancergrace.org/lung/2012/02/25/5takeawaystargetedrx/ http://cancergrace.org/lung/2012/02/25/5takeawaystargetedrx/#comments Sat, 25 Feb 2012 23:30:04 +0000 Dr West http://cancergrace.org/lung/?p=6739 http://cancergrace.org/lung/2012/02/25/5takeawaystargetedrx/feed/ 14 http://cancergrace.org/lung/2012/02/22/belated-introduction-to-dr-charu-aggarwal/ http://cancergrace.org/lung/2012/02/22/belated-introduction-to-dr-charu-aggarwal/#comments Thu, 23 Feb 2012 06:17:25 +0000 Dr West http://cancergrace.org/lung/?p=6599 http://cancergrace.org/lung/2012/02/22/belated-introduction-to-dr-charu-aggarwal/feed/ 11 http://cancergrace.org/lung/2012/02/03/balloons-vs-puddles/ http://cancergrace.org/lung/2012/02/03/balloons-vs-puddles/#comments Fri, 03 Feb 2012 20:59:16 +0000 Dr West http://cancergrace.org/lung/?p=6083 http://cancergrace.org/lung/2012/02/03/balloons-vs-puddles/feed/ 3 http://cancergrace.org/lung/2012/01/29/right-and-wrong-reasons-for-local-rx-in-met-lung-ca/ http://cancergrace.org/lung/2012/01/29/right-and-wrong-reasons-for-local-rx-in-met-lung-ca/#comments Mon, 30 Jan 2012 02:54:54 +0000 Dr West http://cancergrace.org/lung/?p=6081 http://cancergrace.org/lung/2012/01/29/right-and-wrong-reasons-for-local-rx-in-met-lung-ca/feed/ 6 http://cancergrace.org/lung/2012/01/28/pinpoint-molec-assay-lancet-201/ http://cancergrace.org/lung/2012/01/28/pinpoint-molec-assay-lancet-201/#comments Sat, 28 Jan 2012 23:46:01 +0000 Dr West http://cancergrace.org/lung/?p=6078 http://cancergrace.org/lung/2012/01/28/pinpoint-molec-assay-lancet-201/feed/ 5 http://cancergrace.org/lung/2012/01/21/sbrt-long-term-recurrences/ http://cancergrace.org/lung/2012/01/21/sbrt-long-term-recurrences/#comments Sat, 21 Jan 2012 20:53:52 +0000 Dr West http://cancergrace.org/lung/?p=6155 http://cancergrace.org/lung/2012/01/21/sbrt-long-term-recurrences/feed/ 0 http://cancergrace.org/lung/2012/01/16/t790m-mutation/ http://cancergrace.org/lung/2012/01/16/t790m-mutation/#comments Tue, 17 Jan 2012 06:23:29 +0000 Dr West http://cancergrace.org/lung/?p=6072 http://cancergrace.org/lung/2012/01/16/t790m-mutation/feed/ 11 http://cancergrace.org/lung/2012/01/13/mechanisms-of-criz-resistance/ http://cancergrace.org/lung/2012/01/13/mechanisms-of-criz-resistance/#comments Fri, 13 Jan 2012 16:39:48 +0000 Dr West http://cancergrace.org/lung/?p=6070 http://cancergrace.org/lung/2012/01/13/mechanisms-of-criz-resistance/feed/ 9 http://cancergrace.org/lung/2012/01/06/ros1-pos-pts/ http://cancergrace.org/lung/2012/01/06/ros1-pos-pts/#comments Sat, 07 Jan 2012 06:47:18 +0000 Dr West http://cancergrace.org/lung/?p=6068 http://cancergrace.org/lung/2012/01/06/ros1-pos-pts/feed/ 7 http://cancergrace.org/lung/2012/01/04/podcast-on-tobacco-smoking-patterns-and-the-association-with-lung-cancer/ http://cancergrace.org/lung/2012/01/04/podcast-on-tobacco-smoking-patterns-and-the-association-with-lung-cancer/#comments Thu, 05 Jan 2012 02:27:28 +0000 Dr West http://cancergrace.org/lung/?p=6065 http://cancergrace.org/lung/2012/01/04/podcast-on-tobacco-smoking-patterns-and-the-association-with-lung-cancer/feed/ 2 http://cancergrace.org/lung/2011/12/27/her2-mutations-small-numbers-are-suddenly-less-daunting/ http://cancergrace.org/lung/2011/12/27/her2-mutations-small-numbers-are-suddenly-less-daunting/#comments Wed, 28 Dec 2011 06:28:23 +0000 Dr West http://cancergrace.org/lung/?p=6063 http://cancergrace.org/lung/2011/12/27/her2-mutations-small-numbers-are-suddenly-less-daunting/feed/ 0 http://cancergrace.org/lung/2011/12/24/beyond-4-cycles-1st-line/ http://cancergrace.org/lung/2011/12/24/beyond-4-cycles-1st-line/#comments Sat, 24 Dec 2011 22:24:45 +0000 Dr West http://cancergrace.org/lung/?p=6061 http://cancergrace.org/lung/2011/12/24/beyond-4-cycles-1st-line/feed/ 2 http://cancergrace.org/lung/2011/12/21/follow-up-on-avaperl-trial-of-maintenance-alimtaavastin-vs-avastin-alone/ http://cancergrace.org/lung/2011/12/21/follow-up-on-avaperl-trial-of-maintenance-alimtaavastin-vs-avastin-alone/#comments Wed, 21 Dec 2011 18:00:54 +0000 Dr West http://cancergrace.org/lung/?p=6059 http://cancergrace.org/lung/2011/12/21/follow-up-on-avaperl-trial-of-maintenance-alimtaavastin-vs-avastin-alone/feed/ 0 http://cancergrace.org/lung/2011/12/18/challenging-cases-in-lung-cancer-acquired-resistance-to-an-egfr-inhibitor-in-a-patient-with-advanced-nsclc-and-egfr-mutation/ http://cancergrace.org/lung/2011/12/18/challenging-cases-in-lung-cancer-acquired-resistance-to-an-egfr-inhibitor-in-a-patient-with-advanced-nsclc-and-egfr-mutation/#comments Sun, 18 Dec 2011 20:06:24 +0000 Dr West http://cancergrace.org/lung/?p=6054 http://cancergrace.org/lung/2011/12/18/challenging-cases-in-lung-cancer-acquired-resistance-to-an-egfr-inhibitor-in-a-patient-with-advanced-nsclc-and-egfr-mutation/feed/ 0 http://cancergrace.org/lung/2011/12/07/yankelevitz-lung-nodules-podcast/ http://cancergrace.org/lung/2011/12/07/yankelevitz-lung-nodules-podcast/#comments Thu, 08 Dec 2011 03:27:57 +0000 Dr West http://cancergrace.org/lung/?p=5809 http://cancergrace.org/lung/2011/12/07/yankelevitz-lung-nodules-podcast/feed/ 0 Here's the podcast from the recent webinar by Dr. David Yankelevitz, Professor of Radiology at Mount Sinai Medical Center in New York City, on the subject of "Pulmonary Nodules: Evaluation and Management".  He took us through a wonderful review of many... Here's the podcast from the recent webinar by Dr. David Yankelevitz, Professor of Radiology at Mount Sinai Medical Center in New York City, on the subject of "Pulmonary Nodules: Evaluation and Management".  He took us through a wonderful review of many recent developments in CT scans, both in screening programs and informal workup of many other medical settings, as well as how the best radiologists distinguish higher from lower risk nodules.  He also covered the work-up of higher risk nodules with CT-guided biopsies. One key point: a huge proportion of lung nodules aren't cancer, and as our CT scanners get more sensitive, we're going to be finding nodules in just about everyone.  But when they're that common, it's not really appropriate to call them abnormal. Below is the audio and video versions of the podcast, as well as the transcript and figures: dr-yankelevitz-pulm-nodules-evaluation-and-management-audio-podcast dr-yankelevitz-pulm-nodules-evaluation-and-management-transcript dr-yankelevitz-pulm-nodules-evaluation-and-management-figures This was another webinar in the terrific expert series that we developed in partnership with LUNGevity Foundation.  Thanks to both Dr. Yankelevitz and LUNGevity for making this great program possible.  I hope it's helpful. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5809-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/12/03/chest-trial-scagliotti-neoadjuvant-chemotherapy/ http://cancergrace.org/lung/2011/12/03/chest-trial-scagliotti-neoadjuvant-chemotherapy/#comments Sat, 03 Dec 2011 13:45:21 +0000 Dr West http://cancergrace.org/lung/?p=5799 http://cancergrace.org/lung/2011/12/03/chest-trial-scagliotti-neoadjuvant-chemotherapy/feed/ 1 http://cancergrace.org/lung/2011/11/29/bac-today/ http://cancergrace.org/lung/2011/11/29/bac-today/#comments Tue, 29 Nov 2011 12:26:03 +0000 Dr West http://cancergrace.org/lung/?p=5794 http://cancergrace.org/lung/2011/11/29/bac-today/feed/ 7 http://cancergrace.org/lung/2011/11/24/qa-on-alk-inhibitor-therapy/ http://cancergrace.org/lung/2011/11/24/qa-on-alk-inhibitor-therapy/#comments Thu, 24 Nov 2011 23:53:49 +0000 Dr West http://cancergrace.org/lung/?p=5788 http://cancergrace.org/lung/2011/11/24/qa-on-alk-inhibitor-therapy/feed/ 1 ALK inhibitor,ALK Rearrangement,ALK translocation,ALK-positive,crizotinib,EML4-ALK,XALKORI Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on the science and clinical experience with the novel ALK inhibitor XALKORI (crizotinib), we had a question and answer session, which is now available as a podcast. Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on the science and clinical experience with the novel ALK inhibitor XALKORI (crizotinib), we had a question and answer session, which is now available as a podcast. Here's the audio podcast and transcript for it (not really a video component for this one). drs-solomon-and-camidge-qa-on-alk-inhibition-transcript Thanks to Drs. Solomon and Camidge for their participation, and to LUNGevity Foundation for partnering with us to make this program and so many others in the series of webinars and podcasts on lung cancer topics possible. GRACE :: Lung Cancer no 12:45 http://cancergrace.org/lung/2011/11/22/smoking-cessation-and-ct-screening-teachable-moment/ http://cancergrace.org/lung/2011/11/22/smoking-cessation-and-ct-screening-teachable-moment/#comments Tue, 22 Nov 2011 14:01:51 +0000 Dr West http://cancergrace.org/lung/?p=5785 http://cancergrace.org/lung/2011/11/22/smoking-cessation-and-ct-screening-teachable-moment/feed/ 1 http://cancergrace.org/lung/2011/11/20/challenges-of-managing-elderly-patient/ http://cancergrace.org/lung/2011/11/20/challenges-of-managing-elderly-patient/#comments Mon, 21 Nov 2011 01:40:59 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5775 http://cancergrace.org/lung/2011/11/20/challenges-of-managing-elderly-patient/feed/ 1 http://cancergrace.org/lung/2011/11/15/tobacco-and-smoking-cessation-mark-millard/ http://cancergrace.org/lung/2011/11/15/tobacco-and-smoking-cessation-mark-millard/#comments Wed, 16 Nov 2011 01:32:24 +0000 Dr West http://cancergrace.org/lung/?p=5753 http://cancergrace.org/lung/2011/11/15/tobacco-and-smoking-cessation-mark-millard/feed/ 0 http://cancergrace.org/lung/2011/11/13/ros-1-mutation-prelim/ http://cancergrace.org/lung/2011/11/13/ros-1-mutation-prelim/#comments Mon, 14 Nov 2011 00:10:31 +0000 Dr West http://cancergrace.org/lung/?p=5746 http://cancergrace.org/lung/2011/11/13/ros-1-mutation-prelim/feed/ 4 http://cancergrace.org/lung/2011/11/12/rc-on-molecular-screening-and-post-criz-acquired-resistance/ http://cancergrace.org/lung/2011/11/12/rc-on-molecular-screening-and-post-criz-acquired-resistance/#comments Sat, 12 Nov 2011 16:04:34 +0000 Dr West http://cancergrace.org/lung/?p=5740 http://cancergrace.org/lung/2011/11/12/rc-on-molecular-screening-and-post-criz-acquired-resistance/feed/ 0 alimta,ALK inhibitor,ALK Rearrangement,Camidge,crizotinib,HSP 90,IPI-504,Molecular Markers,molecular screening,pemetrexed,STA-9090,XALKORI Continuing with Dr. Ross Camidge as our focus (see yesterday's post for a brief update from him on the afatinib/cetuximab trial), today let's turn to the recent webinar program he and Dr. Ben Solomon did with us on the subject of ALK Inhibition: From B... Continuing with Dr. Ross Camidge as our focus (see yesterday's post for a brief update from him on the afatinib/cetuximab trial), today let's turn to the recent webinar program he and Dr. Ben Solomon did with us on the subject of ALK Inhibition: From Biology to FDA-Approved Therapy for Advanced NSCLC". After Dr. Solomon provided an excellent summary of the biology and early clinical experience with XALKORI (crizotinib) that was so impressive in (the admittedly limited population of) ALK-positive patients, Dr. Camidge led us through the second part of the program. His focus was on the practical implications from here: with a newly approved therapy of XALKORI tied to a rather uncommon molecular marker, who should we be screening for it? And what are the options for these patients after they develop acquired resistance to XALKORI? Here is the presentation by Dr. Camidge in audio and video podcast format, along with the associated transcript and figures for the program: dr-camidge-on-molecular-screening-and-postcriz-rx-audio-podcast dr-camidge-on-molecular-screening-and-postcriz-rx-transcript dr-camidge-on-molecular-screening-and-postcriz-rx-figures We'll soon have the question and answer session from this webinar program available as a podcast for you. Between now and then, I'll next be moving from Ross to a newly-identified mutation called ROS-1 and worked on largely by...wait for it... Dr. Ross Camidge. Special thanks to the LUNGevity Foundation for partnering with us to make this program and all of our lung cancer-related activities possible. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5740-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/11/11/rc-about-afatinib-cetuximab/ http://cancergrace.org/lung/2011/11/11/rc-about-afatinib-cetuximab/#comments Fri, 11 Nov 2011 23:31:35 +0000 Dr West http://cancergrace.org/lung/?p=5734 http://cancergrace.org/lung/2011/11/11/rc-about-afatinib-cetuximab/feed/ 14 http://cancergrace.org/lung/2011/11/06/systematic-undertreatment/ http://cancergrace.org/lung/2011/11/06/systematic-undertreatment/#comments Mon, 07 Nov 2011 02:07:24 +0000 Dr West http://cancergrace.org/lung/?p=5731 http://cancergrace.org/lung/2011/11/06/systematic-undertreatment/feed/ 10 http://cancergrace.org/lung/2011/11/03/pulsed-tarceva-for-lmc/ http://cancergrace.org/lung/2011/11/03/pulsed-tarceva-for-lmc/#comments Fri, 04 Nov 2011 00:41:58 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5724 http://cancergrace.org/lung/2011/11/03/pulsed-tarceva-for-lmc/feed/ 18 http://cancergrace.org/lung/2011/10/31/ben-solomon-alk-inhib-podcast/ http://cancergrace.org/lung/2011/10/31/ben-solomon-alk-inhib-podcast/#comments Mon, 31 Oct 2011 16:17:31 +0000 Dr West http://cancergrace.org/lung/?p=5715 http://cancergrace.org/lung/2011/10/31/ben-solomon-alk-inhib-podcast/feed/ 2 alimta,ALK,crizotinib,EML4-ALK,HSP90,HSP90 inhibitor,molecular marker,molecular testing,pemetrexed,XALKORI Several weeks ago, we were fortunate enough to be joined by not one but two international stars in lung cancer research that is being translated directly from lab bench to bedside of the patient. I don't think there's a more clear and inspiring exampl... Several weeks ago, we were fortunate enough to be joined by not one but two international stars in lung cancer research that is being translated directly from lab bench to bedside of the patient. I don't think there's a more clear and inspiring example of good science leading to effective therapy, albeit for a limited patient population, than the story of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (recently FDA approved and commercially launched as XALKORI) for patients with an EML4-ALK rearrangement (approximately 4% of the broader NSCLC population). Drs. Ben Solomon from Peter MacCallum Cancer Centre in Melbourne, Australia, and Ross Camidge from University of Colorado, in Denver, collaborated with a handful of other international researchers from all over the world to study crizotinib and conduct the critical trials, shepherding its development into a treatment now available to help a targeted subset of patients with this targeted therapy. Dr. Ben Solomon spoke first, providing an overview of the (short) history of the EML4-ALK translocation and how crizotinib began to be studied in the first patients. He then took us on a tour of the highlights of both the efficacy data for this new agent and the side effect profile. Here's the audio and video podcast versions of his presentation, along with pdf files of the accompanying transcript and figures: dr-solomon-alk-inhibition-science-to-approved-therapy-audio-podcast dr-solomon-alk-inhibition-science-to-approved-therapy-transcript dr-solomon-alk-inhibition-science-to-approved-therapy-figures This is the first of the series of podcasts from this program on ALK inhibition. The next one, coming very soon, will cover Dr. Camidge's presentation, which covered practical issues such as screening for ALK and alternative treatment options for ALK-positive patients. Special thanks to LUNGevity Foundation for partnering with GRACE to make the live program and these subsequent podcasts possible. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5715-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/10/28/auy922-hsp90/ http://cancergrace.org/lung/2011/10/28/auy922-hsp90/#comments Fri, 28 Oct 2011 16:53:32 +0000 Dr. Johnson http://cancergrace.org/lung/?p=5709 http://cancergrace.org/lung/2011/10/28/auy922-hsp90/feed/ 8 http://cancergrace.org/lung/2011/10/23/lux-lung-1-results-in-detail/ http://cancergrace.org/lung/2011/10/23/lux-lung-1-results-in-detail/#comments Sun, 23 Oct 2011 22:18:47 +0000 Dr West http://cancergrace.org/lung/?p=5705 http://cancergrace.org/lung/2011/10/23/lux-lung-1-results-in-detail/feed/ 8 http://cancergrace.org/lung/2011/10/18/talactoferrin-jco-2011/ http://cancergrace.org/lung/2011/10/18/talactoferrin-jco-2011/#comments Tue, 18 Oct 2011 21:50:21 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5690 http://cancergrace.org/lung/2011/10/18/talactoferrin-jco-2011/feed/ 11 http://cancergrace.org/lung/2011/10/17/acosog-z0040-ln-oms/ http://cancergrace.org/lung/2011/10/17/acosog-z0040-ln-oms/#comments Mon, 17 Oct 2011 15:58:14 +0000 Dr West http://cancergrace.org/lung/?p=5685 http://cancergrace.org/lung/2011/10/17/acosog-z0040-ln-oms/feed/ 2 http://cancergrace.org/lung/2011/10/15/lilenbaum-elderly-lung-cancer-qa-session/ http://cancergrace.org/lung/2011/10/15/lilenbaum-elderly-lung-cancer-qa-session/#comments Sat, 15 Oct 2011 17:47:23 +0000 Dr West http://cancergrace.org/lung/?p=5678 http://cancergrace.org/lung/2011/10/15/lilenbaum-elderly-lung-cancer-qa-session/feed/ 0 elderly,Frail,Performance Status 2,Poor Risk,PS2 Following the excellent podcast by Dr. Rogerio Lilenbaum, lung cancer expert and now Chair of Cleveland Clinic Florida in Weston, on Considerations and Challenges of Treating Elderly Patients with Lung Cancer, Following the excellent podcast by Dr. Rogerio Lilenbaum, lung cancer expert and now Chair of Cleveland Clinic Florida in Weston, on Considerations and Challenges of Treating Elderly Patients with Lung Cancer, he fielded questions from me and the folks in the live audience who attended. Here's that question and answer session, provided in audio and with the associated transcript. There isn't really any video/figures for this one. dr-lilenbaum-qa-on-treating-lung-cancer-in-elderly-pts-transcript As always, thanks very much to LUNGevity Foundation for working with GRACE to make the webinar and podcast possible. GRACE :: Lung Cancer no 8:27 http://cancergrace.org/lung/2011/10/07/rtog-0617-high-vs-low-dose-rt-2/ http://cancergrace.org/lung/2011/10/07/rtog-0617-high-vs-low-dose-rt-2/#comments Fri, 07 Oct 2011 19:32:51 +0000 Dr West http://cancergrace.org/lung/?p=5665 http://cancergrace.org/lung/2011/10/07/rtog-0617-high-vs-low-dose-rt-2/feed/ 0 http://cancergrace.org/lung/2011/10/03/lilenbaum-on-lc-in-elderly/ http://cancergrace.org/lung/2011/10/03/lilenbaum-on-lc-in-elderly/#comments Tue, 04 Oct 2011 05:04:43 +0000 Dr West http://cancergrace.org/lung/?p=5657 http://cancergrace.org/lung/2011/10/03/lilenbaum-on-lc-in-elderly/feed/ 0 comorbidity,elderly,poor performance status,Poor Risk,PS2,quoix Here's the presentation by my friend and colleague Dr. Rogerio Lilenbaum, a great medical oncologist now serving as Director of Hematology/Oncology at the Cleveland Clinic Foundation in South Florida (Weston, FL). Here's the presentation by my friend and colleague Dr. Rogerio Lilenbaum, a great medical oncologist now serving as Director of Hematology/Oncology at the Cleveland Clinic Foundation in South Florida (Weston, FL). Though he's been renowned in lung cancer in general for many years, he's best known for his particular knowledge and leadership on the topic of managing lung cancer in elderly and frail (variably referred to as poor risk or poor performance status) patients. Here is his talk, in audio and video podcast format, along with the associated figures and transcript: dr-lilenbaum-on-treating-lung-cancer-in-elderly-pts-audio-podcast dr-lilenbaum-on-treating-lung-cancer-in-elderly-pts-figs dr-lilenbaum-on-treating-lung-cancer-in-elderly-pts-transcript His presentation includes a general perspective on principles of treating elderly patients and how we should be making recommendations, along with a summary of the evidence on chemotherapy for patients with resected early stage NSCLC, locally advanced NSCLC, and advanced/metastatic disease. It's a great overview of a big topic, and I hope it's very helpful. We'll follow with a podcast of the live question and answer session that followed his presentation. Thanks to LUNGevity Foundation for partnering with GRACE to develop this program. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5657-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/09/26/avaperl-prelim-results/ http://cancergrace.org/lung/2011/09/26/avaperl-prelim-results/#comments Tue, 27 Sep 2011 02:50:09 +0000 Dr West http://cancergrace.org/lung/?p=5654 http://cancergrace.org/lung/2011/09/26/avaperl-prelim-results/feed/ 4 http://cancergrace.org/lung/2011/09/25/stage-iv-non-small-cell-lung-cancer-in-the-elderly-review-of-data-and-update-on-the-published-results-of-the-french-ifct-0501-quoix-trial/ http://cancergrace.org/lung/2011/09/25/stage-iv-non-small-cell-lung-cancer-in-the-elderly-review-of-data-and-update-on-the-published-results-of-the-french-ifct-0501-quoix-trial/#comments Sun, 25 Sep 2011 18:54:26 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5623 http://cancergrace.org/lung/2011/09/25/stage-iv-non-small-cell-lung-cancer-in-the-elderly-review-of-data-and-update-on-the-published-results-of-the-french-ifct-0501-quoix-trial/feed/ 4 http://cancergrace.org/lung/2011/09/20/asc-vs-nccn-guidelines-on-molecular-testing/ http://cancergrace.org/lung/2011/09/20/asc-vs-nccn-guidelines-on-molecular-testing/#comments Wed, 21 Sep 2011 02:42:06 +0000 Dr West http://cancergrace.org/lung/?p=5620 http://cancergrace.org/lung/2011/09/20/asc-vs-nccn-guidelines-on-molecular-testing/feed/ 6 http://cancergrace.org/lung/2011/09/17/who-to-test-for-an-egfr-mutation-or-alk-rearrangement-filtering-based-on-ttf-1-status/ http://cancergrace.org/lung/2011/09/17/who-to-test-for-an-egfr-mutation-or-alk-rearrangement-filtering-based-on-ttf-1-status/#comments Sat, 17 Sep 2011 20:55:34 +0000 Dr West http://cancergrace.org/lung/?p=5618 http://cancergrace.org/lung/2011/09/17/who-to-test-for-an-egfr-mutation-or-alk-rearrangement-filtering-based-on-ttf-1-status/feed/ 2 http://cancergrace.org/lung/2011/09/11/brain-metastases-in-lung-cancer-still-room-to-personalize-care/ http://cancergrace.org/lung/2011/09/11/brain-metastases-in-lung-cancer-still-room-to-personalize-care/#comments Sun, 11 Sep 2011 17:32:09 +0000 Dr Loiselle http://cancergrace.org/lung/?p=5615 http://cancergrace.org/lung/2011/09/11/brain-metastases-in-lung-cancer-still-room-to-personalize-care/feed/ 15 http://cancergrace.org/lung/2011/09/07/alimta-for-alk-pos-nsclc-lee-jto/ http://cancergrace.org/lung/2011/09/07/alimta-for-alk-pos-nsclc-lee-jto/#comments Wed, 07 Sep 2011 13:14:01 +0000 Dr West http://cancergrace.org/lung/?p=5608 http://cancergrace.org/lung/2011/09/07/alimta-for-alk-pos-nsclc-lee-jto/feed/ 1 http://cancergrace.org/lung/2011/08/30/unresectable-stage-iiib-nsclc-casepodcase/ http://cancergrace.org/lung/2011/08/30/unresectable-stage-iiib-nsclc-casepodcase/#comments Wed, 31 Aug 2011 00:22:17 +0000 Dr West http://cancergrace.org/lung/?p=5598 http://cancergrace.org/lung/2011/08/30/unresectable-stage-iiib-nsclc-casepodcase/feed/ 1 chemoradiation,consolidation,docetaxel,locally advanced NSCLC,stage III NSCLC,taxotere Here's another case in the recording I did with Drs. Jyoti Patel from Northwestern and Bob Doebele from University of Colorado, discussing a series of perplexing cases in lung cancer management, then combining their comments with the responses from sev... Here's another case in the recording I did with Drs. Jyoti Patel from Northwestern and Bob Doebele from University of Colorado, discussing a series of perplexing cases in lung cancer management, then combining their comments with the responses from several other terrific experts (Drs. Suresh Ramalingam, Jonathan Goldman, Julie Brahmer, Heather Wakelee, and Karen Reckamp) about the same case. From each one, you can get a sense of the variability in how different lung cancer experts share the same set of data but have their own interpretation and style for cases where there are significant gaps in what the data tell us. This particular case is one we struggle with all the time, and one for which many people have asked questions here. Once someone with unresectable stage III NSCLC has completed initial chemo/radiation, typically over an approximately seven week period, should we recommend any additional treatment after that. We are generally tempted to do so, in hopes of providing better results than what we might expect without it, but we don't have evidence that it helps. I think you'll get a clear sense of the uncertainty (at least mine), but several of the speakers also note their different mindset for those patients treated with weekly carbo/Taxol (paclitaxel) (which we believe doesn't give meaningful systemic dosing to eradicate micrometastatic disease, but it can help make the radiation given concurrently more effective) versus "full dose" cisplatin/etoposide (which we feel does treat possible distant disease in addition to helping make the radiation more effective where it is directed). So here's the audio and video versions of the podcast, along with the transcript and figures from the presentation. grace-cases-stage-iiib-nsclc-chemort-and-consolidation-q-audio-podcast grace-cases-stage-iiib-nsclc-chemort-and-consolidation-q-transcript grace-cases-stage-iiib-nsclc-chemort-and-consolidation-q-figures We've got several more case-based podcasts in this series, but the next in the queue is the webinar by Dr. Mario Lacouture on managing skin, hair, and nail-related side effects in cancer patients. Look for that one soon! GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5598-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/08/27/alk-inhibitor-xalkori-crizotinib-fda-approved-new-era-with-new-challenges/ http://cancergrace.org/lung/2011/08/27/alk-inhibitor-xalkori-crizotinib-fda-approved-new-era-with-new-challenges/#comments Sat, 27 Aug 2011 15:47:41 +0000 Dr West http://cancergrace.org/lung/?p=5592 http://cancergrace.org/lung/2011/08/27/alk-inhibitor-xalkori-crizotinib-fda-approved-new-era-with-new-challenges/feed/ 7 http://cancergrace.org/lung/2011/08/20/asco-highlights-in-lung-cancer-qa-session/ http://cancergrace.org/lung/2011/08/20/asco-highlights-in-lung-cancer-qa-session/#comments Sun, 21 Aug 2011 02:29:50 +0000 Dr West http://cancergrace.org/lung/?p=5569 http://cancergrace.org/lung/2011/08/20/asco-highlights-in-lung-cancer-qa-session/feed/ 3 ASCO 2011 ALERT: The links for the podcasts are now fixed. - Here's the question and answer session with Drs. Mary Pinder and Nasser Hanna following their presentations on the lung cancer highlights from the ASCO 2011 annual meeting (Dr. Pinder's on SCLC, ALERT: The links for the podcasts are now fixed. Here's the question and answer session with Drs. Mary Pinder and Nasser Hanna following their presentations on the lung cancer highlights from the ASCO 2011 annual meeting (Dr. Pinder's on SCLC, early stage NSCLC, and mesothelioma here, and Dr. Hanna's on advanced NSCLC here), covering a lot of ground on timely issues raised from the conference. The program and podcast were developed in partnership with LUNGevity Foundation. Below is the audio and video versions of the podcast, as well as the transcript and figures. asco-2011-highlights-in-lung-cancer-qa-audio-podcast asco-2011-highlights-in-lung-cancer-qa-session-transcript asco-2011-highlights-in-lung-cancer-qa-session-figures But if that list of questions and answers doesn't cover every question YOU have in response to the ASCO presentations, feel free to ask the stragglers here. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5569-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/08/19/when-do-recurrences-of-lung-cancer-happen-after-surgery/ http://cancergrace.org/lung/2011/08/19/when-do-recurrences-of-lung-cancer-happen-after-surgery/#comments Fri, 19 Aug 2011 15:56:20 +0000 Dr West http://cancergrace.org/lung/?p=5564 http://cancergrace.org/lung/2011/08/19/when-do-recurrences-of-lung-cancer-happen-after-surgery/feed/ 7 http://cancergrace.org/lung/2011/08/16/ihc-score-on-flex/ http://cancergrace.org/lung/2011/08/16/ihc-score-on-flex/#comments Tue, 16 Aug 2011 13:19:46 +0000 Dr West http://cancergrace.org/lung/?p=5553 http://cancergrace.org/lung/2011/08/16/ihc-score-on-flex/feed/ 1 http://cancergrace.org/lung/2011/08/12/sacrilegious-thoughts-on-adjuvant-chemo-for-nsclc/ http://cancergrace.org/lung/2011/08/12/sacrilegious-thoughts-on-adjuvant-chemo-for-nsclc/#comments Fri, 12 Aug 2011 22:24:00 +0000 Dr West http://cancergrace.org/lung/?p=5551 http://cancergrace.org/lung/2011/08/12/sacrilegious-thoughts-on-adjuvant-chemo-for-nsclc/feed/ 1 http://cancergrace.org/lung/2011/08/09/limits-of-ct-scanning/ http://cancergrace.org/lung/2011/08/09/limits-of-ct-scanning/#comments Wed, 10 Aug 2011 05:02:19 +0000 Dr West http://cancergrace.org/lung/?p=5547 http://cancergrace.org/lung/2011/08/09/limits-of-ct-scanning/feed/ 5 http://cancergrace.org/lung/2011/08/04/asco-highlights-in-advanced-nsclc-by-dr-nasser-hanna/ http://cancergrace.org/lung/2011/08/04/asco-highlights-in-advanced-nsclc-by-dr-nasser-hanna/#comments Fri, 05 Aug 2011 01:39:38 +0000 Dr West http://cancergrace.org/lung/?p=5541 http://cancergrace.org/lung/2011/08/04/asco-highlights-in-advanced-nsclc-by-dr-nasser-hanna/feed/ 5 acquired resistance,Advanced NSCLC,afatinib,ALK Rearrangement,cetuximab,crizotinib,EGFR mutation,EML4-ALK,Lung Cancer Mutation Consortium,maintenance therapy,PARAMOUNT trial Here's the second talk from our recent webinar, partnering with LUNGevity Foundation to cover the ASCO Highlights in Lung Cancer, and this talk followed after the presentation by Dr. Mary Pinder on highlights in SCLC, early stage NSCLC, Here's the second talk from our recent webinar, partnering with LUNGevity Foundation to cover the ASCO Highlights in Lung Cancer, and this talk followed after the presentation by Dr. Mary Pinder on highlights in SCLC, early stage NSCLC, and mesothelioma and covered developments in advanced NSCLC. Dr. Nasser Hanna, an international leader in the field from Indiana University, summarized the most important new data in this arena. Below you'll find links to the audio and video versions of the podcast, as well as the transcript and figures from his talk. hanna-asco-2011-highlights-advanced-nsclc-audio-podcast hanna-asco-2011-highlights-advanced-nsclc-transcript hanna-asco-2011-highlights-advanced-nsclc-figures The third and final podcast in this series will be the question and answer session, which will be out shortly. As always, we welcome your questions and comments here. On behalf of GRACE and LUNGevity Foundation, we hope you find this webinar content helpful. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5541-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/07/23/egfr-mutations-in-adenocarcinoma/ http://cancergrace.org/lung/2011/07/23/egfr-mutations-in-adenocarcinoma/#comments Sat, 23 Jul 2011 21:00:52 +0000 Dr West http://cancergrace.org/lung/?p=5530 http://cancergrace.org/lung/2011/07/23/egfr-mutations-in-adenocarcinoma/feed/ 3 http://cancergrace.org/lung/2011/07/20/first-asco-highlights-podcast-dr-pinder-on-small-cell-early-stage-nsclc-and-mesothelioma/ http://cancergrace.org/lung/2011/07/20/first-asco-highlights-podcast-dr-pinder-on-small-cell-early-stage-nsclc-and-mesothelioma/#comments Wed, 20 Jul 2011 18:38:46 +0000 Dr West http://cancergrace.org/lung/?p=5524 http://cancergrace.org/lung/2011/07/20/first-asco-highlights-podcast-dr-pinder-on-small-cell-early-stage-nsclc-and-mesothelioma/feed/ 1 adjuvant chemotherapy,amrubicin,malignant pleural mesothelioma,obatoclax,relapsed SCLC Several weeks ago, we were fortunate enough to have Dr. Mary Pinder (alternately referred to as Pinder-Schenck) from the H. Lee Moffitt Cancer Center in Tampa join as the first of two speakers reviewing highlights in thoracic oncology from ASCO. Several weeks ago, we were fortunate enough to have Dr. Mary Pinder (alternately referred to as Pinder-Schenck) from the H. Lee Moffitt Cancer Center in Tampa join as the first of two speakers reviewing highlights in thoracic oncology from ASCO. She covered several key presentations in small cell lung cancer, early stage non-small cell lung cancer, and mesothelioma. Here's the audio and video versions of the podcast, along with the transcript and figures (a zip file to decompress, since it was too big in unzipped form to upload) for this program: pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-audio-podcast pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-transcript pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-figures This program will be followed by Dr. Nasser Hanna's presentation of the highlights from advanced NSCLC at ASCO 2011, and then question and answer time as an additional podcast. The live webinar, as well as all of these podcasts, were developed in partnership with LUNGevity Foundation. We're very grateful for their support. And for those of you reminded of how much you like Dr. Pinder, don't worry -- she's coming back for September. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5524-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/07/17/pf-299804-shows-trend-toward-survival-benefit-vs-tarceva/ http://cancergrace.org/lung/2011/07/17/pf-299804-shows-trend-toward-survival-benefit-vs-tarceva/#comments Sun, 17 Jul 2011 17:10:21 +0000 Dr West http://cancergrace.org/lung/?p=5516 http://cancergrace.org/lung/2011/07/17/pf-299804-shows-trend-toward-survival-benefit-vs-tarceva/feed/ 11 http://cancergrace.org/lung/2011/07/15/xgevavszometascagliottiwclc/ http://cancergrace.org/lung/2011/07/15/xgevavszometascagliottiwclc/#comments Fri, 15 Jul 2011 18:42:30 +0000 Dr West http://cancergrace.org/lung/?p=5507 http://cancergrace.org/lung/2011/07/15/xgevavszometascagliottiwclc/feed/ 10 http://cancergrace.org/lung/2011/07/10/challenging-cases-in-lung-cancer-stage-iiia-n2-node-positive-nsclc-debatably-resectable/ http://cancergrace.org/lung/2011/07/10/challenging-cases-in-lung-cancer-stage-iiia-n2-node-positive-nsclc-debatably-resectable/#comments Sun, 10 Jul 2011 19:53:15 +0000 Dr West http://cancergrace.org/lung/?p=5501 http://cancergrace.org/lung/2011/07/10/challenging-cases-in-lung-cancer-stage-iiia-n2-node-positive-nsclc-debatably-resectable/feed/ 2 induction therapy,mediastinal N2 lymph nodes,neoadjuvant chemotherapy,resectable,Stage IIIA As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lung cancer discussed with multiple experts, here's one on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC. As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lung cancer discussed with multiple experts, here's one on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC. This is among the most controversial clinical settings in lung cancer, as illustrated by the wide range of answers of how the experts in this program would manage the same patient. Some of the experts even note that the way that such a patient would be managed at their center would depend on the people weighing in on the case. This also underscores how important a multidisciplinary approach, often developed in a "tumor board" conference, is for developing treatment plans, ideally by a consensus among the various medical specialists involved. Here's the audio podcast, video podcast, and transcript for the program (really not much video to follow for this one). grace-cases-stage-iiia-n2-nsclc-of-questionable-resectability-audio-podcast grace-cases-stage-iiia-n2-nsclc-of-questionable-resectability-transcript We'd love to hear your comments and questions. There are still several more interesting cases in this series, but we'll take a break from them for a while to bring you the podcasts for the ASCO Lung Cancer Highlights webinar from a couple of weeks ago. Look for those over the next couple of weeks. And thanks again to LUNGevity Foundation for their support in developing the case series, the ASCO highlights program, and the podcasts for all of these activities! GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5501-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/07/07/world-lung-conference-day-4-772011/ http://cancergrace.org/lung/2011/07/07/world-lung-conference-day-4-772011/#comments Thu, 07 Jul 2011 12:38:36 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5490 http://cancergrace.org/lung/2011/07/07/world-lung-conference-day-4-772011/feed/ 10 http://cancergrace.org/lung/2011/07/06/world-lung-conference-day-3-762011/ http://cancergrace.org/lung/2011/07/06/world-lung-conference-day-3-762011/#comments Wed, 06 Jul 2011 16:03:02 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5471 http://cancergrace.org/lung/2011/07/06/world-lung-conference-day-3-762011/feed/ 5 http://cancergrace.org/lung/2011/07/05/world-lung-conference-day-2-752011/ http://cancergrace.org/lung/2011/07/05/world-lung-conference-day-2-752011/#comments Tue, 05 Jul 2011 13:36:22 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5459 http://cancergrace.org/lung/2011/07/05/world-lung-conference-day-2-752011/feed/ 8 http://cancergrace.org/lung/2011/07/04/world-lung-conference-day-1-742011/ http://cancergrace.org/lung/2011/07/04/world-lung-conference-day-1-742011/#comments Mon, 04 Jul 2011 15:07:46 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5446 http://cancergrace.org/lung/2011/07/04/world-lung-conference-day-1-742011/feed/ 6 http://cancergrace.org/lung/2011/07/03/challenging-cases-adjuvant-chemo-for-smaller-node-neg-nsclc-higher-risk/ http://cancergrace.org/lung/2011/07/03/challenging-cases-adjuvant-chemo-for-smaller-node-neg-nsclc-higher-risk/#comments Sun, 03 Jul 2011 21:28:02 +0000 Dr West http://cancergrace.org/lung/?p=5442 http://cancergrace.org/lung/2011/07/03/challenging-cases-adjuvant-chemo-for-smaller-node-neg-nsclc-higher-risk/feed/ 0 adjuvant chemotherapy,node-negative,Stage I,T stage,tumor size Continuing with this series of case-based podcasts we've done in partnership with LUNGevity, we'll again have a series of experts offer their own perspective to another challenging scenario. All are with the same format of me hosting and presenting t... Continuing with this series of case-based podcasts we've done in partnership with LUNGevity, we'll again have a series of experts offer their own perspective to another challenging scenario. All are with the same format of me hosting and presenting the case to Drs. Bob Doebele from University of Colorado and Jyoti Patel from Northwestern University, who participated in the live webinar version of this, then followed in the recording by other terrific colleagues of mine weighing on the same case. These experts are: Dr. Suresh Ramalingam, from Winship Cancer Center, Emory University in Atlanta, GA, Dr. Jonathan Goldman, from Premier Oncology in Santa Monica, CA. Dr. Julie Brahmer, from Sydney Kimmel Cancer Center at Johns Hopkins University, in Baltimore, MD Dr. Heather Wakelee, from Stanford University Cancer Center in Palo Alto, CA Dr. Karen Reckamp, from City of Hope Cancer Center in Duarte, CA This case is of a woman with a tumor that is in the range that is smaller than that for which we would routinely recommend post-operative (adjuvant) chemotherapy to reduce the risk of recurrence, but the tumor has some higher risk features that lead her, and might lead us, to be more inclined to recommend it despite the smaller size of the tumor (which is still within a pretty debatable range). Here's the links to the audio and video versions of the podcast, along with the transcript: adjuvant-chemo-for-smaller-nsclc-tumor-with-high-risk-features-audio-podcast adjuvant-chemo-for-smaller-nsclc-tumor-with-high-risk-features-transcript There are still several more cases coming, on a wide range of topics in lung cancer, so keep looking for those in the coming weeks to months. Thanks again to LUNGevity for their support, and to our faculty for their time and thoughtful comments. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5442-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/06/29/the-national-lung-screening-trial-results-are-in/ http://cancergrace.org/lung/2011/06/29/the-national-lung-screening-trial-results-are-in/#comments Thu, 30 Jun 2011 01:10:06 +0000 Dr Hensing http://cancergrace.org/lung/?p=5440 http://cancergrace.org/lung/2011/06/29/the-national-lung-screening-trial-results-are-in/feed/ 0 http://cancergrace.org/lung/2011/06/26/details-on-the-debate-over-who-to-test-and-for-what-molecular-markers/ http://cancergrace.org/lung/2011/06/26/details-on-the-debate-over-who-to-test-and-for-what-molecular-markers/#comments Sun, 26 Jun 2011 19:46:55 +0000 Dr West http://cancergrace.org/lung/?p=5437 http://cancergrace.org/lung/2011/06/26/details-on-the-debate-over-who-to-test-and-for-what-molecular-markers/feed/ 0 http://cancergrace.org/lung/2011/06/25/reflex-testing-in-lung-cancer-who-to-test-and-when/ http://cancergrace.org/lung/2011/06/25/reflex-testing-in-lung-cancer-who-to-test-and-when/#comments Sat, 25 Jun 2011 15:13:56 +0000 Dr West http://cancergrace.org/lung/?p=5430 http://cancergrace.org/lung/2011/06/25/reflex-testing-in-lung-cancer-who-to-test-and-when/feed/ 2 http://cancergrace.org/lung/2011/06/12/adjuv-chemo-satellite-lesion/ http://cancergrace.org/lung/2011/06/12/adjuv-chemo-satellite-lesion/#comments Sun, 12 Jun 2011 18:06:20 +0000 Dr West http://cancergrace.org/lung/?p=5423 http://cancergrace.org/lung/2011/06/12/adjuv-chemo-satellite-lesion/feed/ 6 adjuvant chemotherapy,early stage NSCLC,resected NSCLC,satellite lesion This is the first of a series of podcasts we've done, developed in partnership with LUNGevity Foundation, in which I present the same challenging cases in lung cancer management to a series of experts to learn the range of views offered by them, This is the first of a series of podcasts we've done, developed in partnership with LUNGevity Foundation, in which I present the same challenging cases in lung cancer management to a series of experts to learn the range of views offered by them, then the multiple thoughtful comments by all of them discussing the same single featured case for each podcast. The first discussants in each podcast will be Drs. Bob Doebele from University of Colorado and Jyoti Patel from Northwestern University, who are then followed by other terrific colleagues of mine: Dr. Suresh Ramalingam, from Winship Cancer Center, Emory University in Atlanta, GA, Dr. Jonathan Goldman, from Premier Oncology in Santa Monica, CA. Dr. Julie Brahmer, from Sydney Kimmel Cancer Center at Johns Hopkins University, in Baltimore, MD Dr. Heather Wakelee, from Stanford University Cancer Center in Palo Alto, CA Dr. Karen Reckamp, from City of Hope Cancer Center in Duarte, CA Our first case is a discussion of how they would approach a patient who has a small primary tumor that also has a separate microscopic satellite lesion nearby. Here's the links to the audio and video versions of the podcast (there isn't a lot of video to see, by the way), along with the transcript: case series: small nsclc tumor w/satellite lesion video podcast case series: small nsclc tumor w/satellite lesion audio podcast case-series-small-nsclc-tumor-wsatellite-lesion-transcript Apologies that the video viewer within the post isn't installed, as it was in the prior version of the site. The tech folks will add that in very soon. We'll be releasing a new podcast discussing an interesting case every couple of weeks. Big thanks to our great guest faculty for the program, as well as to LUNGevity Foundation. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5423-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/06/09/janjigian-acquired-resistance-to-egfr-tkis-cetuximab-afatinib/ http://cancergrace.org/lung/2011/06/09/janjigian-acquired-resistance-to-egfr-tkis-cetuximab-afatinib/#comments Thu, 09 Jun 2011 14:24:12 +0000 Dr Pennell http://cancergrace.org/lung/?p=5418 http://cancergrace.org/lung/2011/06/09/janjigian-acquired-resistance-to-egfr-tkis-cetuximab-afatinib/feed/ 18 http://cancergrace.org/lung/2011/06/07/amrubicin-recap-from-asco/ http://cancergrace.org/lung/2011/06/07/amrubicin-recap-from-asco/#comments Tue, 07 Jun 2011 23:37:39 +0000 Dr West http://cancergrace.org/lung/?p=5402 http://cancergrace.org/lung/2011/06/07/amrubicin-recap-from-asco/feed/ 1 http://cancergrace.org/lung/2011/06/05/quick-update-from-asco/ http://cancergrace.org/lung/2011/06/05/quick-update-from-asco/#comments Sun, 05 Jun 2011 21:08:16 +0000 Dr West http://cancergrace.org/lung/?p=5399 http://cancergrace.org/lung/2011/06/05/quick-update-from-asco/feed/ 5 http://cancergrace.org/lung/2011/05/14/balancing-risks-of-undertreatment-vs-overtreatment-of-locally-advanced-nsclc/ http://cancergrace.org/lung/2011/05/14/balancing-risks-of-undertreatment-vs-overtreatment-of-locally-advanced-nsclc/#comments Sat, 14 May 2011 22:48:37 +0000 Dr West http://cancergrace.org/lung/?p=5381 http://cancergrace.org/lung/2011/05/14/balancing-risks-of-undertreatment-vs-overtreatment-of-locally-advanced-nsclc/feed/ 2 http://cancergrace.org/lung/2011/04/24/interview-with-dr-tony-mok-part-2/ http://cancergrace.org/lung/2011/04/24/interview-with-dr-tony-mok-part-2/#comments Mon, 25 Apr 2011 00:35:52 +0000 Dr West http://cancergrace.org/lung/?p=5372 http://cancergrace.org/lung/2011/04/24/interview-with-dr-tony-mok-part-2/feed/ 5 http://cancergrace.org/lung/2011/04/19/tony-mok-interview-part-1/ http://cancergrace.org/lung/2011/04/19/tony-mok-interview-part-1/#comments Tue, 19 Apr 2011 16:09:07 +0000 Dr West http://cancergrace.org/lung/?p=5314 http://cancergrace.org/lung/2011/04/19/tony-mok-interview-part-1/feed/ 5 http://cancergrace.org/lung/2011/04/12/qa-with-dr-sequist/ http://cancergrace.org/lung/2011/04/12/qa-with-dr-sequist/#comments Wed, 13 Apr 2011 03:33:55 +0000 Dr West http://cancergrace.org/lung/?p=5272 http://cancergrace.org/lung/2011/04/12/qa-with-dr-sequist/feed/ 2 acquired resistance,EGFR,EGFR TKI,NSCLC,repeat biopsy,T790M,T790M mutation The third and last podcast from our discussions with Dr. Lecia Sequist, of Massachusetts General Hospital and Harvard Medical School, covers the question & answer session that followed her excellent webinar on acquired resistance to EGFR tyrosine kinas... The third and last podcast from our discussions with Dr. Lecia Sequist, of Massachusetts General Hospital and Harvard Medical School, covers the question & answer session that followed her excellent webinar on acquired resistance to EGFR tyrosine kinase inhibitors, as well as the update I did with her on the latest information from their experience of re-biopsying lung tumors over the course of treatment. Here are the audio and video versions of the podcast, as well as the transcript. sequist-qa-session-audio-podcast sequist-qa-session-transcript I'll note that we didn't include every question, but these are many of them that would likely be most appealing to a broad audience. Feel free to leave other questions, and either one of us on the GRACE faculty or perhaps Dr. Sequist may be able to provide some thoughts. I hope people learned something from the webinar and the series of podcasts. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5272-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/04/10/fgf-in-lung-cance/ http://cancergrace.org/lung/2011/04/10/fgf-in-lung-cance/#comments Sun, 10 Apr 2011 23:39:35 +0000 Dr. Weiss http://cancergrace.org/lung/?p=5252 http://cancergrace.org/lung/2011/04/10/fgf-in-lung-cance/feed/ 6 http://cancergrace.org/lung/2011/04/05/dr-lecia-sequist-on-the-value-of-repeat-biopsies-with-ongoing-treatment-of-lung-cancer/ http://cancergrace.org/lung/2011/04/05/dr-lecia-sequist-on-the-value-of-repeat-biopsies-with-ongoing-treatment-of-lung-cancer/#comments Tue, 05 Apr 2011 20:37:52 +0000 Dr West http://cancergrace.org/lung/?p=5236 http://cancergrace.org/lung/2011/04/05/dr-lecia-sequist-on-the-value-of-repeat-biopsies-with-ongoing-treatment-of-lung-cancer/feed/ 8 acquired resistance,biopsy,EGFR mutations,EGFR resistance,lung cancer subtypes,pathologic diagnosis,resistance mutation Here's a continuation of the webinar content by Dr. Lecia Sequist, who is an Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH). At the time of her live presentation, Here's a continuation of the webinar content by Dr. Lecia Sequist, who is an Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH). At the time of her live presentation, she was unable to discuss some very new work that was about to be published on their experience at MGH in repeating biopsies on patients over the course of their ongoing treatment, and the interesting and sometimes treatment-changing results they found. This second podcast includes her presentation on this very timely information that was, frankly, surprising to many in the lung cancer community, as well as to the investigators themselves. The presentation is in video and audio podcast forms, along with the associated transcript and figures. sequist-on-lessons-learned-from-serial-biopsies-audio-podcast sequist-on-lessons-learned-from-serial-biopsies-transcript sequist-on-lessons-learned-from-serial-biopsies-figures We welcome your comments and questions. The last podcast, which we'll release next week, will include the Q&A session and discussion that followed her presentation. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5236-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/03/29/dr-sequist-on-acquired-resistance-to-egfr-tkis/ http://cancergrace.org/lung/2011/03/29/dr-sequist-on-acquired-resistance-to-egfr-tkis/#comments Wed, 30 Mar 2011 03:39:19 +0000 Dr West http://cancergrace.org/lung/?p=5224 http://cancergrace.org/lung/2011/03/29/dr-sequist-on-acquired-resistance-to-egfr-tkis/feed/ 4 acquired resistance,c-MET,EGFR mutation,erlotinib,gefitinib,Iressa,Met,T790M,tarceva,Tissue sampling A few weeks ago, Dr. Lecia Sequist, Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH), joined us for a live webinar we did in partnership with LUNGevity Foundation. Dr. A few weeks ago, Dr. Lecia Sequist, Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH), joined us for a live webinar we did in partnership with LUNGevity Foundation. Dr. Sequist and her colleagues at MGH have been at the forefront of research in EGFR mutations: her group was among the first to identify activating mutations and observe the correlation with response to EGFR tyrosine kinase inhibitors (TKIs), and they continue to do much of the leading clinical research on acquired resistance -- the development of progression after an initial good response -- and potential mechanisms for reversing this. In the presentation below, provided in video and audio podcast forms (along with the associated transcript and figures), she provides an outline of the issue and some of the identified mechanisms for resistance. In addition, she discusses several attempts to manage this and current and emerging clinical trial options for this setting. sequist-acquired-resistance-to-egfr-tkis-audio-podcast sequist-acquired-resistance-to-egfr-tkis-transcript sequist-acquired-resistance-to-egfr-tkis-figures It's worth noting that Dr. Sequist was unable to discuss the results from a just-published paper that describes the MGH experience of re-biopsying patients over the course of treatment, since that information was still confidential until its publication last week. She recorded a separate brief podcast with me just days ago that is currently in production as a second portion of the podcast, and we'll also include the Q&A exchange from this webinar later. GRACE :: Lung Cancer no <iframe width="640" height="480" src="http://cancergrace.org/lung/?powerpress_embed=5224-podcast&amp;powerpress_player=html5video" frameborder="0" scrolling="no"></iframe> http://cancergrace.org/lung/2011/03/25/braf-inhibitors-in-lung-cancer/ http://cancergrace.org/lung/2011/03/25/braf-inhibitors-in-lung-cancer/#comments Fri, 25 Mar 2011 21:06:37 +0000 Dr. Pinder http://cancergrace.org/lung/?p=5214 http://cancergrace.org/lung/2011/03/25/braf-inhibitors-in-lung-cancer/feed/ 4 http://cancergrace.org/lung/2011/03/19/her2-by-m/ http://cancergrace.org/lung/2011/03/19/her2-by-m/#comments Sat, 19 Mar 2011 20:13:07 +0000 Dr. Pinder http://cancergrace.org/lung/?p=5204 http://cancergrace.org/lung/2011/03/19/her2-by-m/feed/ 8 http://cancergrace.org/lung/2011/03/07/lcmc/ http://cancergrace.org/lung/2011/03/07/lcmc/#comments Tue, 08 Mar 2011 01:45:34 +0000 Dr West http://cancergrace.org/lung/?p=5192 http://cancergrace.org/lung/2011/03/07/lcmc/feed/ 10